



Financial Statements
for the 1st quarter of fiscal year ending March 31, 2018
(From Apr. 1, 2017 to Jun. 30, 2017)

Summary of consolidated results

JMS Co., Ltd.

Company Code No. 7702

August 9, 2017

Highlights in Business Results



(unit: JPY million)

	Results Apr. - Jun. 2016	Results Apr. - Jun. 2017	Diff.	Year- over - Year
Sales	13,336	13,240	(95)	(0.7%)
Operating Income	121	46	(75)	(62.0%)
Ordinary Income	209	148	(60)	(29.0%)
Profit attributable to owners of parent	84	238	153	183.3%
Net Income per share	JPY 1.72	JPY 4.88	---	---

Exchange Rate (average during period)	US Dollar	108.14	111.09
	Euro	127.23	121.08
(unit: JPY)	Singapore Dollar	79.56	79.79

Decreased in sales, but increased in profit(3rd straight year) for the 1st Quarter of FYE Mar. 2018

Sales	Japan	-Increased sales of Closed Mixing/Infusion System for Anticancer Drug "NEO SHIELD" -Declined sales of Infusion Sets
	Overseas	-Increased sales of Blood bag -Decreased sales of Dialyzer


Profit	-Decrease in operating Income, due to the influence of decreased sales and increase in selling cost -Increase in profit attributable to owners of parent, resulting from the adjustment of income tax
--------	--

Sales by segment (geographical area)

(unit: JPY million)

Apr. – Jun. 2016

Apr. – Jun. 2017




*The reporting segment based-classifications have changed from the current term. Please refer to P6.

Profit by segment (geographical area)

(unit: JPY million)

Apr. – Jun. 2016

Apr. – Jun. 2017



*The reporting segment based-classifications have changed from the current term. Please refer to P6.

Summary by segment (geographical area)

(%: year-over-year)



Japan

Sales	9,469 JPY mil.	(4.6%)
Ordinary Income	101 JPY mil.	—%

-Increased sales of Closed Mixing/Infusion System for Anticancer Drug “NEO SHIELD” was offset by the sales drop of Infusion Sets, reducing net sales
 -Despite the influence of sales decrease, the dividend income from associated companies resulted in a profit



Singapore

Sales	4,613 JPY mil.	(1.3%)
Ordinary Income	190 JPY mil.	(11.0%)

-Decreased sales of Hemodialysis blood tubing sets for Japan market reduced net sales
 -The increase of selling cost resulted in a profit

*This segment includes Indonesia local subsidiary.



China

Sales	862 JPY mil.	(9.4%)
Ordinary Income	13 JPY mil.	(78.4%)

-Decreased sales of Dialyzer for the domestic market reduced net sales
 -The influence of sales decrease as well as the increase of selling cost resulted in a profit



Closed-type preparation device for anticancer drugs “NEO SHIELD”

“NEO SHIELD” supports safe and easy handling of anticancer drugs on the medical frontline.

Summary by segment (geographical area)



Philippines

Sales	115 JPY mil.	— %
Ordinary loss	(166) JPY mil.	— %

-Increased sales of Infusion Sets for Japan market raised net sales
 -Loan payable with weak yen reduced loss



Others

Sales	1,899 JPY mil.	4.7%
Ordinary Income	66 JPY mil.	(42.4%)

*This segment includes business activity of domestic subsidiaries, Germany, The United States and South Korea.

(%: year-over-year)



AV Fistula Needle

AV fistula needle is for pulling blood from a patient during a dialysis therapy.

~Due to the revision in the segment classification from this first quarter, the year-to-year comparison has been restated in accordance with these segment changes.~

As the result of the changes;

- With its increased importance, “the Philippines” was added as a reporting segment which was previously included in “Others”.
- Hitherto known as “Germany” and “United States” includes in “Others”.
- Hitherto known as “Southeast Asia” is restated as “Singapore”.
- The previous term’s segment information is in accordance with the new classifications and titles reflecting on changes.


Sales by Business Segment



(unit: JPY million)

Apr. – Jun. 2016

Apr. – Jun. 2017




*Due to organizational reconstructing, the business segment has also changed from the current term.

*The previous term segment information is in accordance with the new classifications and titles reflecting on changes.

Sales by Segment (Customer's Location)

(unit: JPY million)


Apr. – Jun. 2016 Apr. – Jun. 2017



Selling, General and Admin. Expenses



(unit: JPY million)




(unit: JPY million)

	Apr. - Jun. 2016	Apr. - Jun. 2017	Diff.	Year-over-Year
Labor Cost	1,442	1,454	12	0.9%
Transport	380	398	18	4.9%
R & D	335	301	(33)	(10.1%)
Depreciation	104	85	(18)	(18.2%)
Others	1,047	1,121	74	7.1%
Total	3,308	3,361	52	1.6%

Ordinary Income : Compared with the previous year



(unit: JPY million)



The underlined figures exclude impact of exchange rate.

Forecast for FYE Mar. 2018



(unit: JPY million)

	FYE Mar. 2017 Result	FYE Mar. 2018 Forecast	Year-over-Year
Sales	55,574	57,000	2.6%
Operating Income	1,106	1,150	3.9%
Ordinary Income	1,451	1,200	(17.3%)
Profit attributable to owners of parent	1,182	700	(40.8%)
Net Income per share	JPY 24.26	※ JPY 28.73	---

Exchange Rate (average during period)

(unit: JPY)

US Dollar	108.38	110.00	---
Euro	120.33	120.00	---
Singapore Dollar	78.26	79.00	---

※We are planning to carry out a share consolidation as to the shares of common stock of the Company at the ratio of two (2) shares into one (1) share effective as of October 1, 2017.

Topics



-Developing new product "GC-X01", Hemodialysis Machines.

Jun 7, 2017

-Notice of Share Consolidation, Change of Number of Shares in Share Unit, and Partial Amendment of Articles of Incorporation.

Apr. 19, 2017

-Developing new product "JMS InnerSure Ace",
Pancreaticojejunostomy assist device.

Mar. 13, 2017

-Establishing "Dalian CDDS technical center" in China.

Feb. 20, 2017



Hemodialysis Machines
"GC-X01"



The Bridge to Good Health Care

The assessment figures described on this report are based on available information at this moment, including uncertain data. Actual results may be different from the figures.